English
Spanishwelcome to oneGRAVESvoice
- a positively charged Graves' disease and thyroid eye disease community.- join today!
- log in
FDA Committee Unanimously Recommends Approval of Teprotumumab for Thyroid Eye Disease
The Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA voted 12-0 Friday in favor of recommending approval of a biologics license application for teprotumumab, an experimental human monoclonal antibody shown to dramatically reduce the most debilitating symptoms of Graves’ orbitopathy.
Committee members expressed concern before casting votes about the small patient population studied — fewer than 90 adults treated with infusions of teprotumumab (Horizon Therapeutics) have been enrolled in controlled clinical trials — and several adverse events reported, among them hearing loss, muscle spasms, hyperglycemia and infections. In briefing materials, the FDA noted the population was considerably smaller than the common safety database of greater than 300 patients treated with a course of therapy. However, committee members ultimately agreed that the benefits of the drug outweighed any potential risks.
rareRelated
-
Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth DriversHorizon Therapeutics plc announced today...
-
Jack Ronald Wall, PhDJack Ronald Wall is a Professor of Medic...
-
Brian Chuck Tse, MDBrian Chuck Tse is an Assistant Professo...
-
Maria Antonietta Altea, MDMaria Antonietta Altea, MD, is associate...
-
Shira L. Robbins, MD, FAAO, FAAPShira Robbins is Clinical Professor and ...
-
Thyroid-Associated Ophthalmopathy After Treatment for Graves’ Hyperthyroidism With Antithyroid Drugs or Iodine...Context: Previous randomized trials hav...
-
Graves’ and Thyroid Eye Disease Support Group MeetingThis event is hosted by Graves' Dise...
